Rezolute (NASDAQ: RZLT) provided an important update this week on ersodetug, its investigational antibody for hyperinsulinism: the FDA is continuing to review additional data from…
September 11, 2026
September 11, 2026
Cardiol Therapeutics Files US$150 Million Shelf Prospectus Ahead of CardiolRx Milestones
Key Points Cardiol Therapeutics filed a preliminary US$150 million base shelf prospectus in Canada and a related Form F-10 registration statement with the U.S. Securities…
September 11, 2026
NRx’s HOPE Therapeutics Prepares First Robotic TMS Deployment in Florida
Key Points NRx Pharmaceuticals’ HOPE Therapeutics subsidiary is preparing to deploy Zeta Surgical’s FDA-cleared robotic transcranial magnetic stimulation, or TMS, system in Florida clinics. HOPE…
September 10, 2026
Rhythm Highlights Setmelanotide Benefits in Pediatric Hypothalamic Obesity Studies
Key Points Rhythm Pharmaceuticals presented real-world and Phase 3 data on setmelanotide in children with acquired hypothalamic obesity at ESPE 2026. A French early-access analysis…
September 10, 2026
Oncolytics Reports Preclinical Support for Pelareorep Plus Pan-RAS Inhibitor in Colorectal Cancer
Key Points Oncolytics Biotech reported preclinical results evaluating pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the study’s initial every-other-day pelareorep…
Key Points bioAffinity Technologies regained compliance with Nasdaq’s minimum bid-price and warrants listing requirements. Nasdaq cancelled the company’s previously scheduled hearing before the Nasdaq Hearings…
September 09, 2026
Actuate Reports Preclinical Synergy for Elraglusib With RAS Inhibitors in Pancreatic Cancer
Key Points Actuate Therapeutics reported preclinical data showing that elraglusib enhanced the activity of two investigational RAS-targeted therapies in pancreatic cancer models. The studies tested…
September 09, 2026
Kazia Doses First Patient in Phase 2 Paxalisib Trial for Recurrent AT/RT Brain Cancer
Key Points Kazia Therapeutics dosed the first patient in PNOC035, a Phase 2 study of paxalisib plus gemcitabine for recurrent or progressive AT/RT. The study…
Key Points Opus Genetics reported positive early data from five patients treated with OPGx-BEST1 in a Phase 1/2 study of inherited BEST1-related retinal diseases. All…
Key Points Serina Therapeutics advanced its SER-252 Phase 1b study to Cohort 2 after an independent safety committee reviewed blinded data from the first patient…
September 08, 2026
PDS Biotech Raises Up to $22.55 Million to Advance Cancer Drug Programs
Key Points PDS Biotechnology announced a PIPE financing of up to $22.55 million led by Nant Capital. The company expects an initial $11.55 million closing…
September 08, 2026
Compass Pathways Launches TRD Education Campaign at Psych Congress 2026
Key Points Compass Pathways will introduce its U.S. healthcare-provider education campaign, Change the Tune in TRD, at Psych Congress 2026 in New Orleans. The campaign focuses…